Revium Recovery, Inc. is a biotechnology company focused on the development of highly effective lipid-based therapies that redefine treatment standards. is a pre-clinical stage biopharmaceutical company. The company develops technologies and drug-delivery technological platforms. Its pipeline encompasses antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvant for solid tumors, and an immunization platform. The Company, through its subsidiary, LipoVation Ltd., develops a portfolio of NLP-based pharmaceutical candidates and plans to complete the development and commercialization of a series of medical technologies including: Nanoparticles-based formulation of a potent antibiotic which, based on in vitro and in vivo animal models studies, shows promising potential in combating severe life-threatening antibiotic-resistant bacteria (Nano-Mupirocin); Novel adjuvant to cancer therapies: a nanoparticles-based formulation of angiotensin receptor blockers for intravenous administration (Nano-Candesartan), and Liposomal Protein-Loaded Technology - an approach in immunization through nano particle-based vaccines.
RVRC stock price ended at $1.5 on 月曜日, after rising 188.46%
On the latest trading day Jan 05, 2026, the stock price of RVRC rose by 188.46%, climbing from $1.05 to $1.50. During the session, the stock saw a volatility of 42.86%, with prices oscillating between a daily low of $1.05 and a high of $1.50. Notably, trading volume dropped by 757 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.0K shares were traded, equating to a market value of approximately $117.4K.